Page last updated: 2024-08-23

captopril and valsartan

captopril has been researched along with valsartan in 86 studies

Research

Studies (86)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (4.65)	18.2507
2000's	56 (65.12)	29.6817
2010's	24 (27.91)	24.3611
2020's	2 (2.33)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Leary, A; Lim, P; MacDonald, T; Naas, A; Shiels, P	1
Kullberg, BJ; Netea, MG; Peeters, AC; Thien, T; van der Meer, JW	1
Arwanto, A; Atmoko, R; Kabo, P; Markum, MS; Parsudi, I; Prabowo, P; Prodjosudjadi, W; Soemantri, D; Sukandar, E; Suprihadi, H	1
Botteri, F; Cheung, R; Huff, MW; Lewanczuk, RZ; Muirhead, N; Oddou-Stock, P; Pecher, E; Rodger, NW	1
Califf, R; Edwards, S; Gallo, P; Henis, M; Leizorovicz, A; Maggioni, AP; McMurray, J; Neuhart, E; Pfeffer, MA; Rouleau, JL; Sellers, MA; Van De Werf, F; Velazquez, E	1
Miller, AB; Srivastava, P	1
Kolina, IB; Neverov, NI; Shilov, EM; Shvetsov, MIu; Stavrovskaia, EV; Zakharova, EV	1
Auer, JW; Berent, R; Eber, B	1
Ogihara, T; Rakugi, H	1
Komajda, M	1
de Gasparo, M; Feng, TC; Hua, RJ; Ji, YY; Ying, WY	1
Feely, J; Mahmud, A	1
Becherer, A; Dudczak, R; Karanikas, G; Kletter, K; Wiesner, K	1
Sato, H	1
Allen, TJ; Burrell, LM; Cao, Z; Cooper, ME; Davis, BJ; Lassila, M	1
Califf, RM; Edwards, S; Gallo, P; Henis, M; Kober, L; Leimberger, JD; Maggioni, AP; McMurray, JV; Pfeffer, MA; Rouleau, JL; Sellers, MA; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, HD	1
Deswal, A; Mann, DL	1
Califf, RM; Edwards, S; Henis, M; Køber, L; Leimberger, JD; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Sellers, MA; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, H; Zelenkofske, S	1
Pfeffer, M	1
McAnulty, JH	1
Kupfer, Y; Moshenyat, R; Tessler, S	1
Jorde, UP	1
Liebson, PR	1
Hasenfuss, G	1
Solignac, M	1
Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ	1
Anavekar, NS; Califf, RM; Dickstein, K; Kober, L; Leimberger, JD; Maggioni, A; McMurray, JJ; Nordlander, R; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, EJ; White, HD; Zelenkofske, S	1
Nguyen, A; Sharma, S	1
Xie, XW; Zhao, P	1
Fabbri, G; Maggioni, AP	1
Erhardt, LR	1
Anavekar, NS; Arnold, JM; Barvik, S; Bourgoun, M; Califf, RM; Ghali, JK; Khrakovskaya, M; McMurray, JV; Pfeffer, MA; Schwartz, Y; Skali, H; Solomon, SD; Velazquez, EJ; Warnica, JW	1
DI, J; Huang, ST; Lei, XY; Li, JM; Lu, YS	1
Allsbrook, JS; Califf, RM; Masselink, LE; McMurray, JJ; Pfeffer, MA; Radeva, JI; Reed, SD; Schulman, KA; Sellers, MA; Velazquez, EJ; Weinfurt, KP	1
Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K	1
Aylward, PE; Barvik, S; Califf, RM; Dalby, AJ; Huang, Z; Marin-Neto, JA; McMurray, JJ; Murin, J; Nordlander, RO; Pfeffer, MA; van Gilst, WH; Weaver, WD; White, HD; Zannad, F	1
Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H	1
Califf, RM; Diaz, R; Ertl, G; Køber, L; Leimberger, JD; Maggioni, AP; Mareev, V; McMurray, JJ; Opolski, G; Pfeffer, MA; Rouleau, JL; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; Zannad, F; Zelenkofske, S	1
Califf, RM; Diaz, R; Kober, L; Maggioni, AP; Mareev, V; McMurray, JJ; Murin, J; Reed, SD; Schulman, KA; Van de Werf, F; Velazquez, EJ; White, HD	1
Chen, LF; Ke, YN; Li, N; Zhu, WL	1
Gaskin, FS; Kamada, K; Korthuis, RJ; Yusof, M	1
Aylward, PG; Califf, RM; Kober, L; McMurray, JJ; Pfeffer, MA; Pieper, KS; Skali, H; Solomon, SD; Stephenson, K; Van de Werf, F; Velazquez, EJ; White, HD	1
Ott, P	1
Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S	1
Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ	1
Anavekar, NS; Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, E; White, H	1
Califf, RM; Francis, GS; Huang, Z; Lewis, EF; McMurray, JJ; Pfeffer, MA; Prisant, LM; Thomas, KL; Velazquez, EJ; Weaver, WD	1
Havranek, EP	1
Lu, J; Sun, L; Yu, XJ; Zang, WJ; Zhang, CH	1
Ali, NA; Jawad, AM; Salman, AA	1
Califf, RM; Diaz, R; Leimberger, JD; Lewis, EF; Lokhnygina, Y; McMurray, JJ; Murin, J; Pfeffer, MA; Velazquez, EJ	1
Al-Khatib, SM; Califf, RM; McMurray, JJ; Pfeffer, MA; Piccini, JP; Pieper, K; Solomon, SD; Van de Werf, F; Velazquez, EJ; Zhang, M	1
Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, J; Signorovitch, JE; Solomon, SD; Swedberg, K; Thune, JJ; Velazquez, E	1
Amigoni, M; Califf, R; Køber, L; Levine, RA; McMurray, JJ; Meris, A; Pfeffer, MA; Solomon, SD; Thune, JJ; Velazquez, E; Verma, A	1
Bozcali, E; Dedeoglu, DB; Karpuz, H; Karpuz, V; Suzer, O	1
Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H	1
Chen, Q; Fang, Y; Li, S; Lv, S; Tian, X; Zhou, H	1
Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD	1
Bai, L; Chen, Q; Chen, Y; Du, XJ; Luo, P; Tian, XM; Tian, XZ	1
Flavahan, NA; Flavahan, S; Leung, SW; Vanhoutte, PM; Xu, A; Zhao, Y	1
Califf, R; Claggett, B; Køber, L; Lam, CS; Lewis, E; Liu, J; McEntegart, M; McMurray, JJ; Pfeffer, M; Rouleau, J; Skali, H; Solomon, S; Velazquez, E	1
Adi-Bessalem, S; Laraba-Djebari, F; Sifi, A	1
Bai, L; Chen, Y; Li, XK; Liu, P; Liu, ZQ; Tian, XZ; Xiao, XP	1
Abadir, P; Ansari, A; Berger, A; Beselman, A; Budman, J; Faghih, M; Fedarko, N; Harmon, J; Hosseini, S; Inagami, T; Keenahan, K; Lay, F; Marti, G; Rini, D; Smith, B; Tian, J; Vuong, D; Walston, J	1
Chin, HJ; Kim, YC; Koo, HS; Yu, MY	1
Habara, M; Haraguchi, T; Ikezaki, H; Kojima, H; Nakamura, S; Uchida, T; Yoshida, M	1
Gryciuk, ME; Maciejczyk, M; Mil, KM; Pawlukianiec, C; Zalewska, A; Żendzian-Piotrowska, M; Ładny, JR	1

Reviews

8 review(s) available for captopril and valsartan

Article	Year
Membrane transporters in drug development. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3 Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs	2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. Cardiology clinics, 2001, Volume: 19, Issue:2 Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan	2001
[Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:10 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan	2001
[Acute myocardial infarction]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:10 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Coronary Restenosis; Female; Humans; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan	2002
A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. International journal of clinical practice, 2005, Volume: 59, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Drug Tolerance; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2005
Update on the efficacy of angiotensin receptor blockers in treatment of hypertension. The American journal of managed care, 2005, Volume: 11, Issue:13 Suppl Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Captopril; Diabetes Complications; Drug Evaluation; Humans; Hypertension; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2005
Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and Oxidative medicine and cellular longevity, 2021, Volume: 2021 Topics: Acetylcysteine; Animals; Antioxidants; Captopril; Chloramines; Chromans; Fructose; Glucose; Glycosylation; Humans; Metformin; Oxidation-Reduction; Pyruvaldehyde; Serum Albumin, Bovine; Thioctic Acid; Tosyl Compounds; Valsartan	2021

Trials

26 trial(s) available for captopril and valsartan

Article	Year
The ELITE study. Evaluation of Losartan in the Elderly Study. British journal of clinical pharmacology, 1998, Volume: 45, Issue:6 Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Captopril; Creatine; Cross-Over Studies; Electrocardiography; Heart; Humans; Losartan; Male; Tetrazoles; Valine; Valsartan	1998
A comparison of valsartan and captopril in patients with essential hypertension in Indonesia. International journal of clinical practice, 1999, Volume: 53, Issue:4 Topics: Adult; Aged; Antihypertensive Agents; Captopril; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan	1999
The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. International journal of clinical practice, 1999, Volume: 53, Issue:8 Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Tetrazoles; Valine; Valsartan	1999
Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. American journal of hypertension, 2002, Volume: 15, Issue:4 Pt 1 Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Arteries; Blood Pressure; Captopril; Cross-Over Studies; Drug Synergism; Drug Therapy, Combination; Humans; Hypertension; Middle Aged; Pulse; Tetrazoles; Valine; Valsartan	2002
ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis. European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Humans; Hypertension, Renovascular; Male; Middle Aged; Radioisotope Renography; Radiopharmaceuticals; Renal Artery Obstruction; Reproducibility of Results; Sensitivity and Specificity; Technetium Tc 99m Mertiatide; Tetrazoles; Valine; Valsartan	2002
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The New England journal of medicine, 2003, Nov-13, Volume: 349, Issue:20 Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2003
[AT(1) blocker for post-infarct therapy. VALIANT Study]. Der Internist, 2004, Volume: 45, Issue:8 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Death; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Survival Analysis; Syndrome; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2004
[Results of the VALIANT trial in post-myocardial infarction]. Presse medicale (Paris, France : 1983), 2004, Jun-19, Volume: 33, Issue:11 Topics: Adult; Aftercare; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass Index; Captopril; Cause of Death; Coronary Angiography; Double-Blind Method; Echocardiography; Female; Hospitalization; Humans; Male; Myocardial Infarction; Patient Selection; Proportional Hazards Models; Risk Factors; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan	2004
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. The New England journal of medicine, 2004, Sep-23, Volume: 351, Issue:13 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Chronic Disease; Creatinine; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan	2004
Heart attack patients with complications. Treat with valsartan, captopril, or both? Canadian family physician Medecin de famille canadien, 2004, Volume: 50 Topics: Aged; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2004
VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:3 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan	2005
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation, 2005, Jun-28, Volume: 111, Issue:25 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Electrocardiography; Female; Heart Ventricles; Hospitalization; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American heart journal, 2005, Volume: 150, Issue:2 Topics: Ambulatory Care; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Costs; Global Health; Health Care Costs; Health Resources; Heart Failure; Hospital Costs; Hospitalization; Humans; Myocardial Infarction; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2005
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct Circulation, 2005, Nov-29, Volume: 112, Issue:22 Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Captopril; Cardiovascular Diseases; Cause of Death; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2005
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. European journal of heart failure, 2006, Volume: 8, Issue:6 Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Captopril; Cardiac Output, Low; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2006
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. Heart rhythm, 2007, Volume: 4, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Research Design; Risk Factors; Stroke Volume; Survival Analysis; Survivors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2007
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American heart journal, 2008, Volume: 155, Issue:1 Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction	2008
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. The American journal of cardiology, 2008, Apr-01, Volume: 101, Issue:7 Topics: Aged; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Creatinine; Diabetes Complications; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2008
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). The American journal of cardiology, 2009, Jul-15, Volume: 104, Issue:2 Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan	2009
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. European heart journal, 2010, Volume: 31, Issue:2 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death, Sudden, Cardiac; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Recurrence; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2010
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. European journal of heart failure, 2011, Volume: 13, Issue:2 Topics: Age Factors; Aged; Captopril; Cause of Death; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2011
Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2012, Volume: 25, Issue:5 Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Disease Progression; Echocardiography, Doppler, Color; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Monitoring, Physiologic; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Reference Values; Reproducibility of Results; Risk Assessment; ROC Curve; Severity of Illness Index; Sex Factors; Statistics, Nonparametric; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2012
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:6 Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Captopril; Chi-Square Distribution; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypertrophy, Left Ventricular; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Valine; Valsartan	2012
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC. Heart failure, 2014, Volume: 2, Issue:2 Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan	2014
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European journal of heart failure, 2015, Volume: 17, Issue:3 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Risk; Risk Factors; Sex Factors; Valsartan; Ventricular Dysfunction, Left	2015
Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study. PloS one, 2017, Volume: 12, Issue:11 Topics: Adult; Antihypertensive Agents; Captopril; Creatinine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Male; Middle Aged; Proteinuria; Renin-Angiotensin System; Tacrolimus; Treatment Outcome; Valsartan	2017

Other Studies

52 other study(ies) available for captopril and valsartan

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Prediction of drug intestinal absorption by new linear and non-linear QSPR. European journal of medicinal chemistry, 2011, Volume: 46, Issue:1 Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology, 1998, Volume: 94, Issue:3 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cytokines; Humans; Hypertension; Interleukin-1; Interleukin-6; Lipopolysaccharides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan	1998
Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. American heart journal, 2000, Volume: 140, Issue:5 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cause of Death; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Myocardial Infarction; Odds Ratio; Patient Selection; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Sample Size; Tetrazoles; Valine; Valsartan	2000
[Effects of pathogenetic therapy on blood cholesterol in patients with glomerulonephritis]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:6 Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anticholesteremic Agents; Antihypertensive Agents; Azathioprine; Captopril; Cholesterol; Creatinine; Cyclophosphamide; Data Interpretation, Statistical; Enalapril; Female; Glomerulonephritis; Humans; Immunosuppressive Agents; Lovastatin; Male; Nephrotic Syndrome; Prednisolone; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan	2001
Angiotensin II type 1 receptor blockers and congestive heart failure. Circulation, 2001, Oct-09, Volume: 104, Issue:15 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Receptor, Angiotensin, Type 1; Sample Size; Selection Bias; Tetrazoles; Treatment Outcome; Valine; Valsartan	2001
Are angiotensin II receptor blockers indicated in chronic heart failure? Heart (British Cardiac Society), 2002, Volume: 87, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan	2002
Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2001, Volume: 2, Issue:1 Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Captopril; Carotid Artery Injuries; Cell Division; Endothelin-1; Female; Male; Rabbits; Renin-Angiotensin System; Tetrazoles; Thromboxane B2; Tunica Intima; Valine; Valsartan	2001
Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clinical science (London, England : 1979), 2003, Volume: 104, Issue:4 Topics: Alanine; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Captopril; Cardiomegaly; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Enzyme Inhibitors; Hypertension; Hypertrophy; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European journal of heart failure, 2003, Volume: 5, Issue:4 Topics: Aged; Angiotensin Receptor Antagonists; Captopril; Double-Blind Method; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2003
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose. The New England journal of medicine, 2003, Nov-13, Volume: 349, Issue:20 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2003
[Value in heart failure proven again. AT II blocker soon also for post-infarct patients?]. MMW Fortschritte der Medizin, 2003, Oct-23, Volume: 145, Issue:43 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Survival Rate; Tetrazoles; Valine; Valsartan	2003
Valsartan an alternative to ACE inhibitor in high-risk MI. Geriatrics, 2004, Volume: 59, Issue:1 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2004
[When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent]. MMW Fortschritte der Medizin, 2003, Dec-04, Volume: 145, Issue:49 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2003
[New options against undertreatment]. MMW Fortschritte der Medizin, 2003, Dec-04, Volume: 145, Issue:49 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Hospitalization; Humans; Losartan; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan	2003
These drugs are an ACE in the hole. Angiotensin receptor blockers prove okay when an ACE inhibitor causes problems. Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:6 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Cardiac Output, Low; Cough; Humans; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan	2004
Valsartan, captopril, or both in myocardial infarction. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Ethics, Clinical; Heart Failure; Humans; Myocardial Infarction; Placebos; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2004
Valsartan, captopril, or both in myocardial infarction. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans; Kidney Diseases; Myocardial Infarction; Tetrazoles; Valine; Valsartan	2004
Valsartan, captopril, or both in myocardial infarction. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans; Hypotension; Myocardial Infarction; Tetrazoles; Valine; Valsartan	2004
VALIANT and EUROPA. Preventive cardiology, 2004,Winter, Volume: 7, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2004
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation, 2004, Sep-21, Volume: 110, Issue:12 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2004
[The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice]. [Zhonghua yan ke za zhi] Chinese journal of ophthalmology, 2004, Volume: 40, Issue:11 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Mice; Random Allocation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A	2004
[The effect of captopril and valsartan on preventing the formation of atherosclerotic plaque]. Zhonghua nei ke za zhi, 2005, Volume: 44, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Abdominal; Arteriosclerosis; Captopril; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Male; Rabbits; Tetrazoles; Ultrasonography; Valine; Valsartan	2005
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. European journal of heart failure, 2005, Volume: 7, Issue:5 Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan	2005
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal of the American College of Cardiology, 2006, Feb-21, Volume: 47, Issue:4 Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan	2006
[Successful mega studies with heart patients. Valsartan possesses cardioprotective action]. MMW Fortschritte der Medizin, 2006, Feb-02, Volume: 148, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Long-Term Care; Myocardial Infarction; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan	2006
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American heart journal, 2006, Volume: 152, Issue:3 Topics: Aged; Captopril; Drug Therapy, Combination; Female; Humans; Internationality; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2006
[Effects of valsartan and captopril on expressions and activities of tissue factor and tissue factor pathway inhibitor]. Zhonghua xin xue guan bing za zhi, 2006, Volume: 34, Issue:10 Topics: Animals; Captopril; Cells, Cultured; Endothelium, Vascular; Male; Proton-Translocating ATPases; Rabbits; RNA, Messenger; Tetrazoles; Thromboplastin; Valine; Valsartan	2006
Angiotensin II mediates postischemic leukocyte-endothelial interactions: role of calcitonin gene-related peptide. American journal of physiology. Heart and circulatory physiology, 2007, Volume: 292, Issue:6 Topics: Acetophenones; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcitonin Gene-Related Peptide; Captopril; Cell Adhesion; Chymases; Disease Models, Animal; Endothelial Cells; Imidazoles; Intestines; Ischemia; Leukocyte Rolling; Leukocytes; Male; Mice; Mice, Inbred C57BL; Microscopy, Video; NADPH Oxidases; Pyridines; Pyrimidinones; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Calcitonin Gene-Related Peptide; Reperfusion Injury; Tetrazoles; Valine; Valsartan; Venules	2007
Left bundle branch block is not good for your heart. Heart rhythm, 2007, Volume: 4, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Heart Failure; Humans; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2007
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:1 Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2008
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. Journal of the American College of Cardiology, 2008, May-13, Volume: 51, Issue:19 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Black or African American; Captopril; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Systole; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People	2008
From black and white to shades of gray: race and renin-angiotensin system blockade. Journal of the American College of Cardiology, 2008, May-13, Volume: 51, Issue:19 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Captopril; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People	2008
Ameliorative effect of Captopril and Valsartan on an animal model of diabetic cardiomyopathy. Biological & pharmaceutical bulletin, 2008, Volume: 31, Issue:11 Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiomyopathies; Creatine Kinase, MB Form; Diabetes Mellitus, Experimental; Female; Isoenzymes; L-Lactate Dehydrogenase; Male; Microscopy, Electron; Myocardium; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan	2008
Effects of metronidazole, tinidazole, captopril and valsartan on taste and serum levels of zinc and magnesium. Saudi medical journal, 2009, Volume: 30, Issue:2 Topics: Amebicides; Animals; Antihypertensive Agents; Captopril; Humans; Magnesium; Male; Metronidazole; Rabbits; Random Allocation; Taste; Taste Buds; Tetrazoles; Tinidazole; Valine; Valsartan; Zinc	2009
Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicity. Acta cardiologica, 2012, Volume: 67, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Doxorubicin; Enalapril; Heart Diseases; Hemodynamics; Humans; Male; Rats; Rats, Wistar; Reperfusion Injury; Tetrazoles; Valine; Valsartan	2012
Opiorphin increases blood pressure of conscious rats through renin-angiotensin system (RAS). Peptides, 2014, Volume: 55 Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Hypotension; Hypoxia; Male; Oligopeptides; Rats, Wistar; Renin-Angiotensin System; Salivary Proteins and Peptides; Tetrazoles; Valine; Valsartan	2014
Effects and underlying mechanisms of human opiorphin on cardiovascular activity in anesthetized rats. European journal of pharmacology, 2015, Feb-15, Volume: 749 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Heart Rate; Humans; Male; Naloxone; Narcotic Antagonists; Oligopeptides; Phentolamine; Propranolol; Rats, Sprague-Dawley; Renin-Angiotensin System; Reserpine; Salivary Proteins and Peptides; Tetrazoles; Valine; Valsartan	2015
Elevated pressure causes endothelial dysfunction in mouse carotid arteries by increasing local angiotensin signaling. American journal of physiology. Heart and circulatory physiology, 2015, Feb-15, Volume: 308, Issue:4 Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Carotid Arteries; Endothelium, Vascular; Hydrazines; Hypertension; Indoles; Losartan; Male; Mice; Mice, Inbred C57BL; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Valine; Valsartan; Vasodilation	2015
Role of angiotensin II and angiotensin type-1 receptor in scorpion venom-induced cardiac and aortic tissue inflammation. Experimental and molecular pathology, 2017, Volume: 102, Issue:1 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Captopril; Catalase; Creatine Kinase, MB Form; Cytokines; Eosinophils; Glutathione; Inflammation; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred Strains; Myocardium; Neutrophils; Oxidation-Reduction; Oxidative Stress; Receptor, Angiotensin, Type 1; Scorpion Venoms; Valsartan	2017
Effects of human opiorphin on food intake and water intake in mice following central administration. Neuroscience letters, 2017, 02-22, Volume: 641 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Darkness; Drinking; Eating; Fasting; Humans; Injections, Intraventricular; Male; Mice; Naloxone; Narcotic Antagonists; Oligopeptides; Renin-Angiotensin System; Salivary Proteins and Peptides; Valsartan	2017
Topical Reformulation of Valsartan for Treatment of Chronic Diabetic Wounds. The Journal of investigative dermatology, 2018, Volume: 138, Issue:2 Topics: Administration, Cutaneous; Alloxan; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Chronic Disease; Diabetes Mellitus, Experimental; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor, Angiotensin, Type 1; Skin; Swine; Swine, Miniature; Time Factors; Treatment Outcome; Valsartan; Wound Healing; Wounds and Injuries	2018
A new strategy for taste masking on bitter drug by other combined drug in fixed-dose combination: bitterness of Amlodipine besylate could be masked efficiently by Valsartan. The Journal of pharmacy and pharmacology, 2019, Volume: 71, Issue:9 Topics: Amlodipine; Benzazepines; Captopril; Dose-Response Relationship, Drug; Humans; Hydrochlorothiazide; Taste; Taste Perception; Telmisartan; Valsartan	2019